Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on MRNS. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.50 price objective (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.55 on Thursday. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $10.50. The business has a 50 day moving average of $0.43 and a 200-day moving average of $0.92.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its stake in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares in the last quarter. World Investment Advisors LLC acquired a new position in shares of Marinus Pharmaceuticals during the third quarter worth $104,000. JPMorgan Chase & Co. grew its position in shares of Marinus Pharmaceuticals by 1,968.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 126,752 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals in the second quarter valued at approximately $206,000. Finally, Deltec Asset Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth $107,000. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.